Market Cap
AU$137.0b
Last Updated
2020/10/20 10:36 UTC
Data Sources
Company Financials +
Executive Summary
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. More Details
Snowflake Analysis
Solid track record with adequate balance sheet.
Similar Companies
Share Price & News
How has CSL's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CSL has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.9%
CSL
2.1%
AU Biotechs
0.5%
AU Market
1 Year Return
20.1%
CSL
20.6%
AU Biotechs
-5.6%
AU Market
Return vs Industry: CSL matched the Australian Biotechs industry which returned 20.6% over the past year.
Return vs Market: CSL exceeded the Australian Market which returned -5.6% over the past year.
Shareholder returns
| CSL | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.9% | 2.1% | 0.5% |
| 30 Day | 6.5% | 6.3% | 5.0% |
| 90 Day | 6.5% | 3.5% | 2.9% |
| 1 Year | 21.3%20.1% | 21.7%20.6% | -2.3%-5.6% |
| 3 Year | 122.7%115.2% | 123.2%115.9% | 12.4%-1.2% |
| 5 Year | 247.5%225.7% | 236.5%216.7% | 41.5%12.9% |
Price Volatility Vs. Market
How volatile is CSL's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Shareholders Of CSL (ASX:CSL) Must Be Happy With Their 257% Total Return3 weeks ago | Simply Wall St
How Much Did CSL's (ASX:CSL) CEO Pocket Last Year?1 month ago | Simply Wall St
CSL (ASX:CSL) Has A Pretty Healthy Balance SheetValuation
Is CSL undervalued compared to its fair value and its price relative to the market?
46.04x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CSL (A$301.04) is trading above our estimate of fair value (A$182.52)
Significantly Below Fair Value: CSL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CSL is good value based on its PE Ratio (46x) compared to the XX Biotechs industry average (51.2x).
PE vs Market: CSL is poor value based on its PE Ratio (46x) compared to the Australian market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: CSL is poor value based on its PEG Ratio (3.8x)
Price to Book Ratio
PB vs Industry: CSL is overvalued based on its PB Ratio (14.8x) compared to the AU Biotechs industry average (5.8x).
Next Steps
Future Growth
How is CSL forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
12.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSL's forecast earnings growth (12% per year) is above the savings rate (2.3%).
Earnings vs Market: CSL's earnings (12% per year) are forecast to grow slower than the Australian market (17.5% per year).
High Growth Earnings: CSL's earnings are forecast to grow, but not significantly.
Revenue vs Market: CSL's revenue (9.1% per year) is forecast to grow faster than the Australian market (4.6% per year).
High Growth Revenue: CSL's revenue (9.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CSL's Return on Equity is forecast to be high in 3 years time (28.1%)
Next Steps
Past Performance
How has CSL performed over the past 5 years?
10.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSL has high quality earnings.
Growing Profit Margin: CSL's current net profit margins (23%) are higher than last year (22.5%).
Past Earnings Growth Analysis
Earnings Trend: CSL's earnings have grown by 10.8% per year over the past 5 years.
Accelerating Growth: CSL's earnings growth over the past year (9.6%) is below its 5-year average (10.8% per year).
Earnings vs Industry: CSL earnings growth over the past year (9.6%) exceeded the Biotechs industry 7.3%.
Return on Equity
High ROE: CSL's Return on Equity (32.2%) is considered high.
Next Steps
Financial Health
How is CSL's financial position?
Financial Position Analysis
Short Term Liabilities: CSL's short term assets ($6.4B) exceed its short term liabilities ($2.1B).
Long Term Liabilities: CSL's short term assets ($6.4B) do not cover its long term liabilities ($6.8B).
Debt to Equity History and Analysis
Debt Level: CSL's debt to equity ratio (75.8%) is considered high.
Reducing Debt: CSL's debt to equity ratio has reduced from 82.7% to 75.8% over the past 5 years.
Debt Coverage: CSL's debt is well covered by operating cash flow (50.3%).
Interest Coverage: CSL's interest payments on its debt are well covered by EBIT (20.1x coverage).
Balance Sheet
Next Steps
Dividend
What is CSL current dividend yield, its reliability and sustainability?
0.95%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CSL's dividend (0.95%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.13%).
High Dividend: CSL's dividend (0.95%) is low compared to the top 25% of dividend payers in the Australian market (5.51%).
Stability and Growth of Payments
Stable Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CSL is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.8yrs
Average management tenure
CEO
Paul Perreault (63 yo)
7.25yrs
Tenure
US$11,116,792
Compensation
Mr. Paul R. Perreault, B.A. (Psychology) has been the Chief Executive Officer and Managing Director of CSL Limited since July 1, 2013. Mr. Perreault serves as the Chief Executive Officer and Managing Direc ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD11.12M) is above average for companies of similar size in the Australian market ($USD3.40M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 7.25yrs | US$11.12m | 0.036% $ 49.6m | |
| Chief Financial Officer | 4.75yrs | US$2.99m | 0.0042% $ 5.8m | |
| Chief Operating Officer | 1.25yrs | US$6.83m | 0.00088% $ 1.2m | |
| Senior Adviser & Executive Director | 2yrs | US$2.80m | 0.023% $ 32.1m | |
| Chief Financial Officer | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP of Legal & Group General Counsel | 11.75yrs | US$2.31m | 0% $ 0 | |
| Senior Manager of Communications | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | 2.83yrs | US$1.35m | 0% $ 0 | |
| Executive Vice President of Quality & Business Services | 10.5yrs | US$2.14m | 0% $ 0 | |
| Head of Public Affairs | no data | no data | no data | |
| Department Head of Albumin & Immunoglobulins Production | no data | no data | no data |
4.8yrs
Average Tenure
57yo
Average Age
Experienced Management: CSL's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 7.25yrs | US$11.12m | 0.036% $ 49.6m | |
| Senior Adviser & Executive Director | 2yrs | US$2.80m | 0.023% $ 32.1m | |
| Independent Non Executive Director | 4.67yrs | US$221.26k | 0.00073% $ 999.8k | |
| Independent Non-Executive Director | 0.83yr | US$84.21k | 0.00012% $ 164.4k | |
| Independent Non-Executive Chairman | 2yrs | US$535.99k | 0.035% $ 48.6m | |
| Independent Non-Executive Director | 9.17yrs | US$207.79k | 0.0012% $ 1.7m | |
| Independent Non-Executive Director | 0.17yr | no data | 0.00022% $ 301.3k | |
| Independent Non-Executive Director | 2.67yrs | US$201.39k | 0.000080% $ 109.6k | |
| Independent Non-Executive Director | 7.17yrs | US$195.73k | 0.00069% $ 945.1k |
2.7yrs
Average Tenure
63yo
Average Age
Experienced Board: CSL's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CSL insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
CSL Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CSL Limited
- Ticker: CSL
- Exchange: ASX
- Founded: 1916
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$136.964b
- Shares outstanding: 454.97m
- Website: https://www.csl.com.au
Number of Employees
Location
- CSL Limited
- 45 Poplar Road
- Parkville
- Victoria
- 3052
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CSL | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jun 1994 |
| CSJ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 1994 |
| CMXH.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 1994 |
| CSL | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jun 1994 |
| CSL N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Jun 1994 |
| CSLL.Y | OTCPK (Pink Sheets LLC) | SPON ADR EACH REPR 0.5 ORD | US | USD | Oct 2008 | |
| CSJA | DB (Deutsche Boerse AG) | SPON ADR EACH REPR 0.5 ORD | DE | EUR | Oct 2008 |
Biography
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internat ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/20 10:36 |
| End of Day Share Price | 2020/10/20 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.